Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11439690 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL9126216 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL11435284 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL8817489 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL11435473 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL11439958 | 1.00 | PYGB (0.65) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL11440610 | 0.99 | PYGB (0.67) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL8665848 | 0.93 | PYGB (0.74) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL8669655 | 0.93 | PYGB (0.74) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL8668587 | 0.93 | PYGB (0.74) | PYGBGAAEPHX2PRKCAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231871-A1 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | Shire Human Genetic Therapies, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| CN-106110309-A | The treatment of α galactoside enzyme defect | 夏尔人类遗传性治疗公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-103585621-B | The treatment of alpha-galactoside enzyme defect | 夏尔人类遗传性治疗公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2374876-B1 | Purification process of alpha-galactosidase A | SHIRE HUMAN GENETIC THERAPIES (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-1538202-B1 | Production of human alpha-galactosidase A | SHIRE HUMAN GENETIC THERAPIES (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2186902-B1 | Medical preparations for the treatment of alpha-galactosidase a deficiency | SHIRE HUMAN GENETIC THERAPIES (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110280856-A1 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | SELDEN RICHARD F (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2374876-A2 | Therapy for alpha-galactosidase a deficiency | Shire Human Genetic Therapies, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2327775-A2 | Therapy for alpha-galactosidase a deficiency | Shire Human Genetic Therapies, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2314699-A1 | Medical preparations for the treatment of alpha-galactosidase A deficiency | Shire Human Genetic Therapies, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20030077806-A1 | Composition for use in the treatment of lysosomal storage defects | TRANSKARYOTIC THERAPIES, INC., A DELAWARE CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-6395884-B1 | PURIFYING HUMAN ALPHA GALACTOSIDASE FROM HUMAN CELLS BY PASSING CELLS OVER A HYDROPHOBIC INTERACTION RESIN; THERAPY FOR FABRY'S DISEASE | TRANSKARYOTIC THERAPIES, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1163349-A2 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000053730-A9 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES INC (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000053730-A2 | MEDICAL PREPARATIONS FOR THE TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| US-6083725-A | NUCLEOTIDE SEQUENCES CODING A MAMMALIAN ENZYMATIC POLYPEPTIDE; FOR GENE THERAPY OF LYSOSOMAL STORAGE DEFECT | TRANSKARYOTIC THERAPIES, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0935651-A2 | THERAPY FOR $g(a)-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998011206-A9 | THERAPY FOR α-GALACTOSIDASE A DEFICIENCY | — | 1998-07-02 | — | — | WO | disclosed |
| WO-1998011206-A2 | THERAPY FOR α-GALACTOSIDASE A DEFICIENCY | TRANSKARYOTIC THERAPIES, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5610063-A | GENETIC ENGINEERING | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280856-A1 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY | GLA, GALC, GAA | PYGB 175/4885GAA 3/4885EPHX2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.